The Hematopoietic stem cell transplantation (HSCT) market, estimated at USD 3.56 Bn in 2025, is expected to exhibit a CAGR of 11.2% and reach USD 7.48 Bn by 2032.
The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.
The increasing research and development activities by key market players are expected to drive market growth over the forecast period. For instance, in October 2025, Gamida Cell Ltd., a company providing cell therapies, announced that the Phase 3 study of omidubicel, an investigational advanced cell therapy in development, is a potentially life-saving treatment option for patients in need of a bone marrow transplant and also met all three of its secondary endpoints. In addition, increasing positive activities by the public and private sectors toward bone marrow transplants are also anticipated to surge segment growth.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
COVID-19 had a negative impact on the global hematopoietic stem cell transplantation (HSCT) market owing to slow growth during the pandemic as the treatment of leukemia was delayed in many countries. For instance, according to the study titled "COVID-19 infection in patients with acute leukemia: Istanbul experience," published in August 2025, the proper management of acute leukemia is necessary as it may lead to death if it is not treated promptly. This became a challenge during the pandemic. In addition, several guidelines were also published to decrease mortality in acute leukemia patients. Moreover, it also stated that the management of leukemia patients with COVID-19 infection was also very challenging during the pandemic. Hematopoietic stem cell transplantation is one of the most effective treatments for leukemia. Therefore, such instances indicate that the market witnessed a slow growth rate during the pandemic.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market: Key Developments
On April 17, 2025, Gamida Cell Ltd. announced the U.S. Food and Drug Administration (FDA) approval for Omisirge (omidubicel-onlv), an allogenic cell therapy to reduce the risk of infection in blood cancer patients. Omisirge works by speeding the recovery of neutrophils, a type of white blood cell that combats infection. Specifically, the drug is approved for patients 12 and older who are undergoing umbilical cord blood transplantation following radiation or chemotherapy.
On March 9, 2025, Astellas Pharma Inc., a pharmaceutical company, and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), conducts large, multi-institutional trials, announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) for patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutated acute myeloid leukemia (AML).
In May 2025, Priothera, a late-clinical-stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for mocravimod in combination with allogeneic hematopoietic stem cell transplant (HSCT) for post-remission therapy of acute myeloid leukemia (AML) patients.